Long-term treatment for endometriosis with dienogest: efficacy, side effects and tolerability
Background Dienogest (DNG) improves endometriosis-associated pain (EAP) and patients’ quality of life; however, the modern cornerstone of the management of endometriosis is the long-term adherence of the patient to medical treatment.Objective To evaluate DNG as a long-term treatment of endometriosis...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Gynecological Endocrinology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09513590.2024.2336121 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846110180127801344 |
|---|---|
| author | Francesco La Torre Silvia Vannuccini Federico Toscano Ernesto Gallucci Gretha Orlandi Virginia Manzi Felice Petraglia |
| author_facet | Francesco La Torre Silvia Vannuccini Federico Toscano Ernesto Gallucci Gretha Orlandi Virginia Manzi Felice Petraglia |
| author_sort | Francesco La Torre |
| collection | DOAJ |
| description | Background Dienogest (DNG) improves endometriosis-associated pain (EAP) and patients’ quality of life; however, the modern cornerstone of the management of endometriosis is the long-term adherence of the patient to medical treatment.Objective To evaluate DNG as a long-term treatment of endometriosis, focusing on patients’ compliance and side effects, also correlating with different phenotypes of endometriosis.Methods This was a cohort study on a group of patients with endometriosis (n = 114) undergoing long-term treatment with DNG. During the follow up visits (12, 24, and 36 months) patients were interviewed: an assessment of EAP was performed by using a visual analogue scale (VAS) and side effects were evaluated by using a specific questionnaire of 15 items.Results At 12 months, 81% were continuing the DNG treatment, with a significant reduction of dysmenorrhea, dyspareunia, dyschezia, dysuria and chronic pelvic pain. Of the 19% that discontinued the treatment: 62% was due to spotting, reduced sexual drive, vaginal dryness, and mood disorders. The improvement of EAP was significant for all endometriosis phenotypes, especially in patients with the deep infiltrating type. At 36 months, 73% of patients were continuing the treatment, showing a significant reduction of EAP through the follow up, along with an increase of amenorrhea (from 77% at 12 months to 93% at 36 months). In a subgroup of 18 patients with gastrointestinal disorders, DNG was administered vaginally at the same dosage, showing similar results in terms of efficacy and tolerability.Conclusions DNG was an effective long-term treatment for all endometriosis phenotypes, with few side effects that caused the discontinuation of the treatment mainly during the first year. Thus, the course of 1-year treatment is a predictive indicator for long-term treatment adherence. |
| format | Article |
| id | doaj-art-e102e64c32cb4ba7bd22a9c46cddc0ca |
| institution | Kabale University |
| issn | 0951-3590 1473-0766 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Gynecological Endocrinology |
| spelling | doaj-art-e102e64c32cb4ba7bd22a9c46cddc0ca2024-12-24T14:09:02ZengTaylor & Francis GroupGynecological Endocrinology0951-35901473-07662024-12-0140110.1080/09513590.2024.2336121Long-term treatment for endometriosis with dienogest: efficacy, side effects and tolerabilityFrancesco La Torre0Silvia Vannuccini1Federico Toscano2Ernesto Gallucci3Gretha Orlandi4Virginia Manzi5Felice Petraglia6Division of Obstetrics and Gynecology, Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, AOU Careggi, Florence, ItalyDivision of Obstetrics and Gynecology, Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, AOU Careggi, Florence, ItalyDivision of Obstetrics and Gynecology, Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, AOU Careggi, Florence, ItalyDivision of Obstetrics and Gynecology, Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, AOU Careggi, Florence, ItalyDivision of Obstetrics and Gynecology, Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, AOU Careggi, Florence, ItalyDivision of Obstetrics and Gynecology, Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, AOU Careggi, Florence, ItalyDivision of Obstetrics and Gynecology, Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, AOU Careggi, Florence, ItalyBackground Dienogest (DNG) improves endometriosis-associated pain (EAP) and patients’ quality of life; however, the modern cornerstone of the management of endometriosis is the long-term adherence of the patient to medical treatment.Objective To evaluate DNG as a long-term treatment of endometriosis, focusing on patients’ compliance and side effects, also correlating with different phenotypes of endometriosis.Methods This was a cohort study on a group of patients with endometriosis (n = 114) undergoing long-term treatment with DNG. During the follow up visits (12, 24, and 36 months) patients were interviewed: an assessment of EAP was performed by using a visual analogue scale (VAS) and side effects were evaluated by using a specific questionnaire of 15 items.Results At 12 months, 81% were continuing the DNG treatment, with a significant reduction of dysmenorrhea, dyspareunia, dyschezia, dysuria and chronic pelvic pain. Of the 19% that discontinued the treatment: 62% was due to spotting, reduced sexual drive, vaginal dryness, and mood disorders. The improvement of EAP was significant for all endometriosis phenotypes, especially in patients with the deep infiltrating type. At 36 months, 73% of patients were continuing the treatment, showing a significant reduction of EAP through the follow up, along with an increase of amenorrhea (from 77% at 12 months to 93% at 36 months). In a subgroup of 18 patients with gastrointestinal disorders, DNG was administered vaginally at the same dosage, showing similar results in terms of efficacy and tolerability.Conclusions DNG was an effective long-term treatment for all endometriosis phenotypes, with few side effects that caused the discontinuation of the treatment mainly during the first year. Thus, the course of 1-year treatment is a predictive indicator for long-term treatment adherence.https://www.tandfonline.com/doi/10.1080/09513590.2024.2336121Endometriosisdienogestlong-term treatmentchronic pelvic paintolerability |
| spellingShingle | Francesco La Torre Silvia Vannuccini Federico Toscano Ernesto Gallucci Gretha Orlandi Virginia Manzi Felice Petraglia Long-term treatment for endometriosis with dienogest: efficacy, side effects and tolerability Gynecological Endocrinology Endometriosis dienogest long-term treatment chronic pelvic pain tolerability |
| title | Long-term treatment for endometriosis with dienogest: efficacy, side effects and tolerability |
| title_full | Long-term treatment for endometriosis with dienogest: efficacy, side effects and tolerability |
| title_fullStr | Long-term treatment for endometriosis with dienogest: efficacy, side effects and tolerability |
| title_full_unstemmed | Long-term treatment for endometriosis with dienogest: efficacy, side effects and tolerability |
| title_short | Long-term treatment for endometriosis with dienogest: efficacy, side effects and tolerability |
| title_sort | long term treatment for endometriosis with dienogest efficacy side effects and tolerability |
| topic | Endometriosis dienogest long-term treatment chronic pelvic pain tolerability |
| url | https://www.tandfonline.com/doi/10.1080/09513590.2024.2336121 |
| work_keys_str_mv | AT francescolatorre longtermtreatmentforendometriosiswithdienogestefficacysideeffectsandtolerability AT silviavannuccini longtermtreatmentforendometriosiswithdienogestefficacysideeffectsandtolerability AT federicotoscano longtermtreatmentforendometriosiswithdienogestefficacysideeffectsandtolerability AT ernestogallucci longtermtreatmentforendometriosiswithdienogestefficacysideeffectsandtolerability AT grethaorlandi longtermtreatmentforendometriosiswithdienogestefficacysideeffectsandtolerability AT virginiamanzi longtermtreatmentforendometriosiswithdienogestefficacysideeffectsandtolerability AT felicepetraglia longtermtreatmentforendometriosiswithdienogestefficacysideeffectsandtolerability |